The International Mesothelioma Interest Group sponsored its 7th international meeting in Brescia, Italy from June 24-26, 2004. The meeting, entitled 'How advanced technology and new drugs are changing the perspectives of patients with malignant mesothelioma', was organized by Luciano Mutti (Vercelli, Italy) and GF Tassi (Brescia, Italy) and was attended by 350 participants. The general tone of the meeting was that real progress is now coming in the understanding of mesothelioma biology, progress that may soon translate into improved treatment options. The investigators and clinicians agreed on the importance of referring patients with mesothelioma to centers with expertise where patients can receive the best available treatments and can be offered entry into clinical trials of new and promising agents.

Malignant mesothelioma as both a challenge and an opportunity

Mutti L.;
2004-01-01

Abstract

The International Mesothelioma Interest Group sponsored its 7th international meeting in Brescia, Italy from June 24-26, 2004. The meeting, entitled 'How advanced technology and new drugs are changing the perspectives of patients with malignant mesothelioma', was organized by Luciano Mutti (Vercelli, Italy) and GF Tassi (Brescia, Italy) and was attended by 350 participants. The general tone of the meeting was that real progress is now coming in the understanding of mesothelioma biology, progress that may soon translate into improved treatment options. The investigators and clinicians agreed on the importance of referring patients with mesothelioma to centers with expertise where patients can receive the best available treatments and can be offered entry into clinical trials of new and promising agents.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11697/222937
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact